Blog
Drug Target Encyclopedia Series (17) —CD276
Release Time：
2025-12-05 14:10
CD276 (B7-H3) is an immune checkpoint molecule of the B7 family, highly expressed in many solid tumors but with limited expression in normal tissues. This makes it a promising immuno-oncology target for therapeutic intervention.
CD276 is implicated in:
• Lung cancer (NSCLC, SCLC)
• Breast cancer & triple-negative breast cancer (TNBC)
• Prostate cancer
• Ovarian cancer
• Glioblastoma and other brain tumors
Targeting CD276 in therapy:
- Monoclonal antibodies (mAbs) – Designed to block CD276-mediated immune evasion.
- Antibody-drug conjugates (ADCs) – Link cytotoxic payloads for selective killing of CD276+ tumor cells.
- CAR-T & CAR-NK therapies – Engineering immune cells to directly attack CD276+ cancers.
- Bispecific antibodies – Redirecting T cells against CD276-expressing tumors.
Challenges include:
• Tumor heterogeneity and variable CD276 expression
• On-target/off-tumor safety concerns
• Need for predictive biomarkers for patient stratification
🔬Ongoing research is exploring next-generation ADCs, optimized CAR-T constructs, and combination immunotherapy strategies to unlock the full therapeutic potential of CD276.
Need CD276
Fill out the form below, or visit the link: to browse the complete list of available in-stock products.
E-mail：support@levostar.com
USA
16192 Coastal Hwy，Lewes, DE 19958
TEL：619-537-9202
China
A3-502 No.328, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
TEL：0512-62888898